Drug intelligence / Profile preview

insulin glargine + VIAject

Development stage: Phase 3
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

This appears to be a combination of insulin glargine (a long-acting insulin analog) and VIAject (a rapid-acting insulin). However, there is insufficient information in the provided search results about this specific combination. Insulin glargine is a long-acting synthetic insulin analog that provides a steady level of insulin over 24 hours, while VIAject (also known as Linjeta) is a rapid-acting insulin.

Targets

INSR (Insulin receptor)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on insulin glargine + VIAject.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin glargine + VIAject.